PAI HOLDINGS PHARM
SpecialtyPAI HOLDINGS PHARM is a specialty pharmaceutical company focused on Dermatology, Neurology, Infectious Disease.
PAI HOLDINGS PHARM's Key Drugs
PAI HOLDINGS PHARM's core commercial portfolio centers on SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, spanning Dermatology and Neurology — its most strategically important drugs approved in the last 15 years.
PAI HOLDINGS PHARM's Recent FDA Approvals
New NDA/BLA approvals for PAI HOLDINGS PHARM over the last two years — novel drugs only, excluding generics and label supplements.
PAI HOLDINGS PHARM's Therapeutic Areas
PAI HOLDINGS PHARM's approved drugs and pipeline span 5 therapeutic areas, led by Dermatology and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PAI HOLDINGS PHARM's Top Competitors
PAI HOLDINGS PHARM's closest competitors by therapeutic-area and drug-target overlap include Pfizer, COSETTE, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PAI HOLDINGS PHARM Pipeline Snapshot
Active clinical trials for PAI HOLDINGS PHARM across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 1951-05-03
- Latest
- 2025-12-22
- Applications
- 54